Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. (Q38663903)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

title

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

Nidhi B. Agarwal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Rizwana Parveen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

Neelam Kaushal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

Ghanshyam Mali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

9 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

105-115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

SGLT-2 inhibitors in development for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

SGLT inhibitors: a novel target for diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Canagliflozin: a novel treatment option for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2016.1109629

10.1517/14656566.2016.1109629

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650511 AND SRC:MED&resulttype=core&format=json

2 March 2020

1 reference